Helen Torley, Director, President and Chief Executive Officer, on August 17, 2026, sold 60,000 shares in Halozyme Therapeutics (HALO) for $6,275,592. Following the Form 4 filing with the SEC, Torley has control over a total of 767,780 common shares of the company, with 767,780 shares held directly.
SEC Filing: